Oncogenic potential of SARS-CoV-2—targeting hallmarks of cancer pathways
Authors:
Open Access
- 26 September 2024
- journal article
- review article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-23
Abstract
The 2019 outbreak of SARS-CoV-2 has caused a major worldwide health crisis with high rates of morbidity and death. Interestingly, it has also been linked to cancer, which begs the issue of whether it plays a role in carcinogenesis. Recent studies have revealed various mechanisms by which SARS-CoV-2 can influence oncogenic pathways, potentially promoting cancer development. The virus encodes several proteins that alter key signaling pathways associated with cancer hallmarks. Unlike classical oncogenic viruses, which transform cells through viral oncogenes or by activating host oncogenes, SARS-CoV-2 appears to promote tumorigenesis by inhibiting tumor suppressor genes and pathways while activating survival, proliferation, and inflammation-associated signaling cascades. Bioinformatic analyses and experimental studies have identified numerous interactions between SARS-CoV-2 proteins and cellular components involved in cancer-related processes. This review explores the intricate relationship between SARS-CoV-2 infection and cancer, focusing on the regulation of key hallmarks driving initiation, promotion and progression of cancer by viral proteins. By elucidating the underlying mechanisms driving cellular transformation, the potential of SARS-CoV-2 as an oncovirus is highlighted. Comprehending these interplays is essential to enhance our understanding of COVID-19 and cancer biology and further formulating strategies to alleviate SARS-CoV-2 influence on cancer consequences. Schematic representation of SARS-CoV-2 associated alterations contributing to various hallmarks of cancer. PI3K/ AKT/mTOR: Phosphoinositide 3-kinase/Protein Kinase B/ Mammalian Target of Rapamycin; TGF-β, Transforming Growth Factor-beta; VEGF, Vascular Endothelial Growth Factor; JNK, Jun N-terminal Kinase; HDAC, Histone Deacetylase; DNMT, DNA Methyltransferase; HIF-1α: Hypoxia-Inducible Factor 1-alpha; pRB, Retinoblastoma Protein. This image was created using BioRender software.Keywords
Funding Information
- Indian Council of Medical Research (Cancer-Covid-19, Cancer-Covid-19)
This publication has 180 references indexed in Scilit:
- Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survivalBritish Journal of Cancer, 2006
- RETRACTED: Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding proteinThe International Journal of Biochemistry & Cell Biology, 2006
- Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteinsGenes & Development, 2005
- Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cellsBiochemical and Biophysical Research Communications, 2004
- Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid proteinBiochemical and Biophysical Research Communications, 2003
- Viral mechanisms of immune evasionImmunology Today, 2000
- The Hallmarks of CancerCell, 2000
- High frequency of altered HLA class I phenotypes in invasive breast carcinomasHuman Immunology, 1996
- Cytokines and Growth Factors Induce HSP27 Phosphorylation in Human AstrocytesJournal of Neuropathology & Experimental Neurology, 1995
- Tumor necrosis factor‐α induces changes in the phosphorylation, cellular localization, and oligomerization of human hsp27, a stress protein that confers cellular resistance to this cytokineJournal of Cellular Biochemistry, 1995